Zelboraf (-8%), for BRAF V600 mutation-positive metastatic melanoma. Zelboraf is currently facing significant competition in the US (-42%), whilst in Europe sales were 2% higher. Phase III results from the pivotal coBRIM trial, comparing the combination of cobimetinib (Roche’s investigational MEK inhibitor) with Zelboraf, versus Zelboraf alone were presented at ESMO and published in the New England Journal of Medicine in September. The data showed that combination treatment halved the risk of the disease worsening and the data has been submitted to the European Medicines Agency. The FDA has granted Fast Track Designation for the combination and a US filing will follow later this year.
To the extent CEO hires new staff and embarks on a spending spree, it would be bad. This CEO fired 70% of the staff. So, I think it is now a shell company.
what this company needs now is an activist investor to push for sale of company at say, $5.
The worst chief executives ....I once had an investor say to me at our first meeting “I never trust management, all biotech CEOs lie.” Certainly trust must be ...
Sentiment: Strong Sell
Since I've never claimed to be a scientist or doctor I have to defer to the more knowledgeable posters. It seems that NLNK's immunotherapy drugs are still not approved in any cancer and yet Roche has made a big bet here. They seem to be working on the same cancers that EXEL is working on.
because Onartuzumab has been discontinued as single use I think that also the combination trials wont't be proceeded
clinicaltrials is known
This company is about as exciting as watching paint dry...NASDAQ and DOW up nicley...EXEL down 3-4%...while posts about science are interesting and I really do respect the contibutions that are being made to this site on such topics the goal is to develop and sucessfully sell a produc(s)t before the company runs out of money, a goal which apparently has been lost on the management of this company.
You can find the list of Cobimetinib trials. There is one with Bevacizumab (P2), Onartuzumab (completed P1, October 2014), MPDL3280A (P1b), PII Melanoma Brain Metastases, ....
List goes on..
Been acting odd for a while - range of 1.47 to 1.72. No more talk of Roche Bo in a long time. Would seem to be the time to scoop it up.
cobi will be seen in melanoma first but a lot of other indications could follow - it's unly the beginning of another success story within the oncology powerhouse Genentech/Roche - and EXEL will join this race.
Well I am still in and I haven't sold a single share 3+ years so far that is not looking so good on paper nor does it feel good. But I still believe there is value and I am hanging in until somebody wants to pay me for it.
One of the small clues why contrary investment signals are saying buy this situation. Max pessimism coupled with emotional selling meant panic selling, even when there was good news. Gets way undervalued, with high reward potential. Some now realize this. Those short missed there best, lowest price when there was volume. Now they must edge out and try to keep price down or cover driving price up. Great buy in this price range and on any short term drops. Classic case here, where this IS the best buy time, possibly ever.IMO
Sentiment: Strong Buy